BNP Paribas Financial Markets Acquires 178,366 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

BNP Paribas Financial Markets lifted its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 27.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 831,777 shares of the company’s stock after purchasing an additional 178,366 shares during the quarter. BNP Paribas Financial Markets’ holdings in Kiniksa Pharmaceuticals International were worth $34,311,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in KNSA. Amundi bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Kiniksa Pharmaceuticals International by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after purchasing an additional 1,002 shares during the period. Millennium Management LLC boosted its stake in Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares during the period. Creative Planning bought a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter valued at $358,000. Finally, Quantbot Technologies LP bought a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter valued at $43,000. 53.95% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, May 6th. Finally, Citigroup boosted their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and an average target price of $60.86.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ:KNSA opened at $47.85 on Thursday. The stock has a fifty day moving average price of $50.04 and a 200-day moving average price of $45.56. The company has a market cap of $3.68 billion, a price-to-earnings ratio of 53.17 and a beta of 0.12. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $26.27 and a fifty-two week high of $59.87.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. The firm had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company’s revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.11 EPS. Research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.

Insider Activity

In other news, CAO Michael R. Megna sold 6,625 shares of the company’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $46.69, for a total transaction of $309,321.25. Following the completion of the sale, the chief accounting officer directly owned 27,418 shares in the company, valued at approximately $1,280,146.42. This represents a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 1,703 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $79,513.07. Following the sale, the chief operating officer owned 12,029 shares of the company’s stock, valued at approximately $561,634.01. The trade was a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is owned by insiders.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.